ライフサイエンスコーパス: hydroxyvitamin

1 Compared with 25-hydroxyvitamin D >/=30 ng/ml, 25-hydroxyvitamin D <20 ng

2 stage 3-4 and vitamin D deficiency (serum 25-hydroxyvitamin D </=20 ng/ml).

3 red with 25-hydroxyvitamin D >/=30 ng/ml, 25-hydroxyvitamin D <20 ng/ml was associated with a greater

4 itamin D was categorized as deficiency in 25-hydroxyvitamin D (</= 15 ng/mL), insufficiency (15-30 ng

5 h symptomatic knee osteoarthritis and low 25-hydroxyvitamin D (12.5-60 nmol/L) were enrolled from Jun

6 etermine the association between maternal 25-hydroxyvitamin D (25(OH)D) and the risk of spontaneous p

7 ty of single or predicted measurements of 25-hydroxyvitamin D (25(OH)D) concentration is unknown, as

8 vitamin D status (measured by circulating 25-hydroxyvitamin D (25(OH)D) concentration), adiposity, an

9 lationship between sun exposure and serum 25-hydroxyvitamin D (25(OH)D) concentration.

10 Here, we measured serum 25 hydroxyvitamin D (25(OH)D) concentrations in female Soay

11 Low 25-hydroxyvitamin D (25(OH)D) has been associated with incr

12 Low 25-hydroxyvitamin D (25(OH)D) has been associated with infl

13 To determine whether serum levels of 25-hydroxyvitamin D (25(OH)D) in young adults are associate

14 Research has implicated low 25-hydroxyvitamin D (25(OH)D) level as a risk factor for in

15 ated in dairy foods, and predicted plasma 25-hydroxyvitamin D (25(OH)D) levels were associated with i

16 We investigated whether low 25-hydroxyvitamin D (25(OH)D) levels were associated with m

17 , (2) these associations were modified by 25-hydroxyvitamin D (25(OH)D) status and explained by infla

18 izing the originally measured serum total 25-hydroxyvitamin D (25(OH)D) values from Third National He

19 e examined the association between yearly 25-hydroxyvitamin D (25(OH)D), 1,25-dihydroxyvitamin D (1,2

20 Circulating 25-hydroxyvitamin D (25(OH)D), a marker for vitamin D statu

21 ified SNPs, circulating concentrations of 25-hydroxyvitamin D (25(OH)D), and prostate cancer (3,811 c

22 dian eGFR 51 ml/min per 1.73 m(2)), serum 25-hydroxyvitamin D (25(OH)D), FGF-23, and Klotho levels we

23 e time of radical prostatectomy and serum 25-hydroxyvitamin D (25-OH D) levels.

24 investigated whether the plasma level of 25-hydroxyvitamin D (25-OHD) after a diagnosis of colorecta

25 Serum 25-hydroxyvitamin D (25-OHD) was measured, with VitD status

26 n the relationship between cord levels of 25-hydroxyvitamin D (25[OH]D) and asthma and allergic disea

27 Low plasma 25-hydroxyvitamin D (25[OH]D) concentration is associated w

28 tation of less than 17 weeks, and a serum 25-hydroxyvitamin D (25[OH]D) concentration of 25-100 nmol/

29 exacerbation varied according to baseline 25-hydroxyvitamin D (25[OH]D) concentration, age, ethnic or

30 Deficient 25-hydroxyvitamin D (25[OH]D) concentrations have been asso

31 Adults with low concentrations of 25-hydroxyvitamin D (25[OH]D) in blood have an increased ri

32 icovaginal HPV infection status and serum 25-hydroxyvitamin D (25[OH]D) level were known were studied

33 Low serum 25-hydroxyvitamin D (25[OH]D) levels are associated with an

34 second trimesters of pregnancy and serum 25-hydroxyvitamin D (25[OH]D) levels in mothers during preg

35 aseline differences between patients with 25-hydroxyvitamin D (25[OH]D) levels less than 30 ng/mL vs

36 25-Hydroxyvitamin D (25[OH]D) levels were measured in store

37 ograft recipients who had serum levels of 25-hydroxyvitamin D (25[OH]D) measured within the first 30

38 Levels of 25-hydroxyvitamin D (25[OH]D) were measured in 150 patients

39 Low circulating concentrations of 25-hydroxyvitamin D (25[OH]D), a marker of vitamin D status

40 taneous analysis of vitamin D (Vit D) and 25-hydroxyvitamin D (25OH-Vit D) in meats.

41 tide polymorphisms (SNPs) associated with 25-hydroxyvitamin D (25OHD) level from SUNLIGHT, the larges

42 24[A]), which conferred a large effect on 25-hydroxyvitamin D (25OHD) levels (-0.43 SD of standardize

43 an der Pols et al. observed that baseline 25-hydroxyvitamin D (25OHD) levels above 75 nmol/L were ass

44 morphisms (SNPs) strongly associated with 25-hydroxyvitamin D (25OHD) levels in 33,996 individuals, w

45 -nucleotide polymorphisms associated with 25-hydroxyvitamin D (25OHD) levels in the SUNLIGHT consorti

46 te a serum biomarker of vitamin D status, 25-hydroxyvitamin D (25OHD) measured at the time of breast

47 d as a function of clinical categories of 25-hydroxyvitamin D (p for trend </= 2 x 10(-3)).

48 nted spots was not associated with higher 25-hydroxyvitamin D (P-values > 0.05).

49 l deficiency of the Cyp27b1 gene encoding 25-hydroxyvitamin D 1-alpha-hydroxylase, which produces 1,2

50 in D receptor (rs4334089, rs11568820) and 25-hydroxyvitamin D 1alpha-hydroxylase (CYP27B1: rs4646536)

51 endritic cells, engineered to overexpress 25-hydroxyvitamin D 1alpha-hydroxylase and pulsed with a my

52 25-Hydroxyvitamin D 1alpha-hydroxylase cytochrome P450 (cyp

53 ation with DCs, engineered to overexpress 25-hydroxyvitamin D 1alpha-hydroxylase for de novo synthesi

54 imum concentration of vitamin D3 or serum 25-hydroxyvitamin D [25(OH)D3] lawfully allowed in feed) on

55 ations of the vitamin D hormone precursor 25-hydroxyvitamin D [25(OH)D3]; the high male prevalence of

56 t/obese women (50-75 y of age) with serum 25-hydroxyvitamin D [25(OH)D] >/=10 ng/mL but <32 ng/mL wer

57 verage Requirement (EAR)] or insufficient 25-hydroxyvitamin D [25(OH)D] (<20 ng/mL).

58 investigated associations between plasma 25-hydroxyvitamin D [25(OH)D] (collected 1997 to 2000) and

59 nvestigate the relationship between serum 25-hydroxyvitamin D [25(OH)D] and incidence of allergic rhi

60 Circulating maternal 25-hydroxyvitamin D [25(OH)D] and intact parathyroid hormon

61 implications for the regulation of serum 25-hydroxyvitamin D [25(OH)D] and its catabolism and, conse

62 t increased circulating concentrations of 25-hydroxyvitamin D [25(OH)D] are associated with improved

63 s and to study associations between serum 25-hydroxyvitamin D [25(OH)D] at different developmental st

64 ational survey that includes a measure of 25-hydroxyvitamin D [25(OH)D] by immunoassay.

65 overweight or obese, vitamin D-deficient (25-hydroxyvitamin D [25(OH)D] concentration </=50 nmol/L) a

66 Vitamin D deficiency, defined as a serum 25-hydroxyvitamin D [25(OH)D] concentration <20 ng/mL, is c

67 pulation has poor vitamin D status (serum 25-hydroxyvitamin D [25(OH)D] concentration <25 nmol/L), pa

68 ts (74%) were vitamin D deficient (plasma 25-hydroxyvitamin D [25(OH)D] concentration <50 nmol/L).

69 e, but its efficacy in maintaining infant 25-hydroxyvitamin D [25(OH)D] concentration after birth is

70 e examined the association between plasma 25-hydroxyvitamin D [25(OH)D] concentration and islet autoi

71 Serum 25-hydroxyvitamin D [25(OH)D] concentration has been linked

72 ided for a mean of 8.1 d increased plasma 25-hydroxyvitamin D [25(OH)D] concentrations (P < 0.0001),

73 ed the prospective relation between serum 25-hydroxyvitamin D [25(OH)D] concentrations [which compris

74 amin D intakes required to maintain serum 25-hydroxyvitamin D [25(OH)D] concentrations above proposed

75 intakes required to maintain winter serum 25-hydroxyvitamin D [25(OH)D] concentrations above the prop

76 evious findings of an association between 25-hydroxyvitamin D [25(OH)D] concentrations and periodonta

77 The association between plasma 25-hydroxyvitamin D [25(OH)D] concentrations and prevalence

78 the association between prehospital serum 25-hydroxyvitamin D [25(OH)D] concentrations and risk of HA

79 mined the association between circulating 25-hydroxyvitamin D [25(OH)D] concentrations and the outcom

80 ought to evaluate whether deficient serum 25 hydroxyvitamin D [25(OH)D] concentrations are associated

81 th hepatitis C virus (HCV) monoinfection, 25-hydroxyvitamin D [25(OH)D] concentrations are positively

82 rsy exists over the disparate circulating 25-hydroxyvitamin D [25(OH)D] concentrations between black

83 Low serum 25-hydroxyvitamin D [25(OH)D] concentrations during pregnan

84 Low serum 25-hydroxyvitamin D [25(OH)D] concentrations have been asso

85 Decreased 25-hydroxyvitamin D [25(OH)D] concentrations have been asso

86 his study was to examine whether maternal 25-hydroxyvitamin D [25(OH)D] concentrations in pregnancy a

87 vely study the association between plasma 25-hydroxyvitamin D [25(OH)D] concentrations, vitamin D-rel

88 domized controlled trials (RCTs) on serum 25-hydroxyvitamin D [25(OH)D] concentrations.

89 enes influences ultraviolet (UV)B-induced 25-hydroxyvitamin D [25(OH)D] concentrations.

90 In most studies, serum 25-hydroxyvitamin D [25(OH)D] decreases with increasing BMI

91 en described as being pandemic, but serum 25-hydroxyvitamin D [25(OH)D] distribution data for the Eur

92 er, so far, it is not clear whether serum 25-hydroxyvitamin D [25(OH)D] exerts any beneficial effect

93 The level of serum 25-Hydroxyvitamin D [25(OH)D] has high heritability, sugges

94 ies have suggested that lower circulating 25-hydroxyvitamin D [25(OH)D] in African Americans may part

95 al evidence supports a protective role of 25-hydroxyvitamin D [25(OH)D] in breast carcinogenesis, but

96 The role of maternal 25-hydroxyvitamin D [25(OH)D] in fetal development is uncer

97 clinical significance of low circulating 25-hydroxyvitamin D [25(OH)D] in obese people are unknown.

98 g protein (DBP) is the primary carrier of 25-hydroxyvitamin D [25(OH)D] in the circulation.

99 D], the active vitamin D metabolite, from 25-hydroxyvitamin D [25(OH)D] in the kidney.

100 Epidemiologic data suggest that low serum 25-hydroxyvitamin D [25(OH)D] increases insulin resistance

101 Low 25-hydroxyvitamin D [25(OH)D] is associated with diabetes,

102 Serum 25-hydroxyvitamin D [25(OH)D] is the accepted biomarker for

103 min D deficiency (baseline deseasonalized 25-hydroxyvitamin D [25(OH)D] levels <20 ng/mL).

104 Low plasma 25-hydroxyvitamin D [25(OH)D] levels are associated with hi

105 ed the association between baseline serum 25-hydroxyvitamin D [25(OH)D] levels, supplemental vitamin

106 ncertain because of nonstandardized serum 25-hydroxyvitamin D [25(OH)D] measurements.

107 ciation between prediagnostic circulating 25-hydroxyvitamin D [25(OH)D] serum levels and the risk of

108 ed and reference values for the following 25-hydroxyvitamin D [25(OH)D] species: 25(OH)D2, 25(OH)D3,

109 ionship between body mass index (BMI) and 25-hydroxyvitamin D [25(OH)D] using genetic markers as inst

110 Serum 25-hydroxyvitamin D [25(OH)D] was measured at enrollment, a

111 Baseline serum 25-hydroxyvitamin D [25(OH)D] was not significantly correla

112 Maternal 25-hydroxyvitamin D [25(OH)D] was positively associated wit

113 oratory models, the association of plasma 25-hydroxyvitamin D [25(OH)D] with patient survival is larg

114 d the risk of dementia.We measured plasma 25-hydroxyvitamin D [25(OH)D] with the use of high-performa

115 amin D) and 25-hydroxivitamin D2 plus D3 (25-hydroxyvitamin D [25(OH)D]) in foremilk and hindmilk dur

116 al long bone length, placental VDR, serum 25-hydroxyvitamin D [25(OH)D], 1,25-dihydroxyvitamin D [1,2

117 e evaluated the association between serum 25-hydroxyvitamin D [25(OH)D], a marker of vitamin D status

118 takes, fasting serum parathyroid hormone, 25-hydroxyvitamin D [25(OH)D], and ionized calcium were com

119 of vitamin D, or concentrations of serum 25-hydroxyvitamin D [25(OH)D], no longer increase calcium a

120 g and maintaining serum concentrations of 25-hydroxyvitamin D [25(OH)D], particularly at lower doses

121 from baseline in serum ferritin (SF) and 25-hydroxyvitamin D [25(OH)D], respectively.

122 is currently diagnosed by measuring serum 25-hydroxyvitamin D [25(OH)D].

123 ge and both BMI z score (zBMI) and venous 25-hydroxyvitamin D [25(OH)D]; the secondary objective was

124 The effects of serum vitamin D (25-hydroxyvitamin D [25OHD]) levels on preeclampsia inciden

125 ldren >4 y of age attain sufficient serum 25-hydroxyvitamin D [S-25(OH)D; i.e., >/=50 nmol/L] during

126 us in Finland between 2000 and 2011.Serum 25-hydroxyvitamin D [S-25(OH)D] concentrations of a nationa

127 The 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D levels were

128 Mean (+/- SD) serum total 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D levels were

129 Mean calculated bioavailable 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D were 2.5 +/

130 pplementation rapidly and safely improves 25-hydroxyvitamin D and bioavailable 25-hydroxyvitamin D le

131 evidence of association between change in 25-hydroxyvitamin D and change in 24-hour systolic blood pr

132 id not indicate that associations between 25-hydroxyvitamin D and features of skin aging are causal.

133 This study investigated whether lower 25-hydroxyvitamin D and higher parathyroid hormone concentr

134 Serum 25-hydroxyvitamin D and intact parathyroid hormone were mea

135 elation was observed between bioavailable 25-hydroxyvitamin D and LL-37 (Spearman rho = 0.44; p = 0.0

136 n rho = 0.44; p = 0.03) but not for total 25-hydroxyvitamin D and LL-37.

137 By contrast, 25-hydroxyvitamin D and other markers of mineral metabolism

138 s) and 95% confidence intervals (CIs) for 25-hydroxyvitamin D and parathyroid hormone concentrations

139 teraction between serum concentrations of 25-hydroxyvitamin D and s-retinol on hip fracture was obser

140 Associations between 25-hydroxyvitamin D and skin aging features were tested by

141 Changes in bioavailable 25-hydroxyvitamin D are associated with concomitant increas

142 othesis that low plasma concentrations of 25-hydroxyvitamin D are associated with increased risk of s

143 y age with changes in adiposity and serum 25-hydroxyvitamin D as primary or secondary outcomes were c

144 Variability across studies in 25-hydroxyvitamin D assays and baseline levels, treatment d

145 At a broad population level, 25-hydroxyvitamin D at birth was not associated with risk o

146 Serum 25-hydroxyvitamin D concentration (per 10-nmol/L increment:

147 In contrast, a genetically determined 25-hydroxyvitamin D concentration was not associated with a

148 In addition, vitamin D inadequacy (serum 25-hydroxyvitamin D concentration, averaged across pregnanc

149 Few subjects had 25-hydroxyvitamin D concentrations <30 nmol/L.

150 The intervention elevated 8-week serum 25-hydroxyvitamin D concentrations (154.5 nmol/L vs. 15.2 n

151 m tartrate-resistant acid phosphatase and 25-hydroxyvitamin D concentrations (P < 0.01).

152 her there are causal associations between 25-hydroxyvitamin D concentrations and features of skin agi

153 n model comparing individuals with plasma 25-hydroxyvitamin D concentrations between the 1st and 4th

154 t and 4th percentiles to individuals with 25-hydroxyvitamin D concentrations between the 50th and 100

155 pplementation resulted in increased serum 25-hydroxyvitamin D concentrations compared with placebo (+

156 ation in participants with baseline serum 25-hydroxyvitamin D concentrations of less than 50 nmol/L (

157 Stepwise decreasing plasma 25-hydroxyvitamin D concentrations were associated with ste

158 Lower 25-hydroxyvitamin D concentrations were not associated with

159 25-Hydroxyvitamin D concentrations were not associated with

160 Plasma total 25-hydroxyvitamin D concentrations were originally determin

161 Further studies evaluating 25-hydroxyvitamin D concentrations, other dairy constituent

162 mparing lowest versus highest quartile of 25-hydroxyvitamin D concentrations, the multivariate adjust

163 In the full cohort, 25-hydroxyvitamin D deficiency is a significant predictor f

164 -diagnosed sepsis (n = 444), preadmission 25-hydroxyvitamin D deficiency is a significant predictor f

165 Preadmission 25-hydroxyvitamin D deficiency is predictive for the risk o

166 25-hydroxyvitamin D deficiency prior to hospital admission

167 IU vitamin D2) increased serum levels of 25D-hydroxyvitamin D from 27+/-2 ng/ml before supplementatio

168 Low concentrations of 25-hydroxyvitamin D have been consistently associated with

169 parathyroid hormone (PTH), phosphate, and 25-hydroxyvitamin D in a subset of 420 participants followe

170 We estimated levels of bioavailable 25-hydroxyvitamin D in homozygous participants.

171 The level of 25-hydroxyvitamin D increased more in the vitamin D group (

172 Serum 25-hydroxyvitamin D increased to a similar extent in both g

173 Serum levels of 25-hydroxyvitamin D l <20 ng/ml are diagnostic of vitamin D

174 in adults the associations between serum 25-hydroxyvitamin D level and prevalent asthma as well as a

175 amin D supplementation and milk intake on 25-hydroxyvitamin D level appeared similar regardless of sk

176 The median 25-hydroxyvitamin D level at baseline was 15.3 ng/mL.

177 supplementation and cow's milk, increased 25-hydroxyvitamin D level by 3.4 ng/mL (95% CI, 2-4 ng/mL)

178 al older women with a mean baseline serum 25-hydroxyvitamin D level of 32.8 ng/mL, supplementation wi

179 ients with symptomatic asthma and a serum 25-hydroxyvitamin D level of less than 30 ng/mL was conduct

180 Vitamin D supplementation, but not serum 25-hydroxyvitamin D level or milk intake, was associated wi

181 All patients included had a total 25-hydroxyvitamin D level recorded.

182 65.2 years [SD, 7.0]; mean baseline serum 25-hydroxyvitamin D level, 32.8 ng/mL [SD, 10.5]), 2064 (90

183 ntation and daily volume of cow's milk on 25-hydroxyvitamin D level.

184 0 years of age with low vitamin D status (25-hydroxyvitamin D levels </=25 ng/mL) and systolic blood

185 ogical studies support a link between low 25-hydroxyvitamin D levels and a higher risk of viral upper

186 The 25-hydroxyvitamin D levels and cryptococcal notifications w

187 er respiratory tract infection, and serum 25-hydroxyvitamin D levels at study termination.

188 ICU stay, the percentage of patients with 25-hydroxyvitamin D levels higher than 30 ng/mL at day 7, h

189 rrelation of shorter telomeres with lower 25-hydroxyvitamin D levels in both patients and controls.

190 oves 25-hydroxyvitamin D and bioavailable 25-hydroxyvitamin D levels in patients with severe sepsis o

191 Serum 25-hydroxyvitamin D levels increased by a mean 16.1 ng/mL (

192 lood levels were checked, 289 (74.9%) had 25-hydroxyvitamin D levels of 30 ng/mL or higher by the thi

193 Despite achieving 25-hydroxyvitamin D levels of 41.9 ng/ml (95% confidence in

194 itamin D had a mean net increase in serum 25-hydroxyvitamin D levels of 7.83 ng per milliliter, relat

195 p=0.021), but not in those with baseline 25-hydroxyvitamin D levels of at least 50 nmol/L (1.45, 0.8

196 tion, in patients with COPD with baseline 25-hydroxyvitamin D levels of less than 50 nmol/L.

197 ealth behaviors, and comorbid conditions, 25-hydroxyvitamin D levels under 20 ng/mL remained independ

198 At year 1, serum 25-hydroxyvitamin D levels were 43.9 ng/mL in the vitamin D

199 At study termination, serum 25-hydroxyvitamin D levels were 48.7 ng/mL (95% CI, 46.9-50

200 Serum 25-hydroxyvitamin D levels were measured by using liquid ch

201 Serum 25-hydroxyvitamin D levels within 24 hours of ICU admission

202 BMD by dual-energy x-ray absorptiometry, 25-hydroxyvitamin D levels, and other laboratory assessment

203 tomatic knee osteoarthritis and low serum 25-hydroxyvitamin D levels, vitamin D supplementation, comp

204 s of age and (2) third trimester maternal 25-hydroxyvitamin D levels.

205 sociation between obesity and lower serum 25-hydroxyvitamin D may be due to reversed causation with i

206 ndings: Initial evaluation should include 25-hydroxyvitamin D measurement, 24-hour urine calcium meas

207 (24R),25(OH)2D3) is a major catabolite of 25-hydroxyvitamin D metabolism and is an important vitamin

208 ld, contrasting the stimulatory effect of 25-hydroxyvitamin D or 1,25-dihydroxyvitamin D on related a

209 hepatocytes or monocytes with prohormone 25-hydroxyvitamin D or active 1,25-dihydroxyvitamin D decre

210 n was found between BMD and current serum 25-hydroxyvitamin D or dietary intake of calcium, protein,

211 Elevated PTH, but not 25-hydroxyvitamin D or other markers of mineral metabolism,

212 whites had similar levels of bioavailable 25-hydroxyvitamin D overall (2.9+/-0.1 ng per milliliter an

213 r 2 years at a dose sufficient to elevate 25-hydroxyvitamin D plasma levels to higher than 36 ng/mL,

214 We hypothesized that deficiency in 25-hydroxyvitamin D prior to hospital admission would be as

215 In chromatin immunoprecipitation assays, 25-hydroxyvitamin D promoted binding of the vitamin D recep

216 There was no association between neonatal 25-hydroxyvitamin D quintile and risk of multiple sclerosis

217 We investigated whether 25-hydroxyvitamin D serum concentration was a modifiable ri

218 zed in the liver through hydroxylation to 25-hydroxyvitamin D species, and then further hydroxylated

219 Low 25-hydroxyvitamin D status has been associated with increas

220 ion between allocation and baseline serum 25-hydroxyvitamin D status).

221 94]; p = 0.001) relative to patients with 25-hydroxyvitamin D sufficiency.

222 52]; p = 0.009) relative to patients with 25-hydroxyvitamin D sufficiency.

223 tamin D, local osteoblastic conversion of 25-hydroxyvitamin D to 1,25-dihydroxyvitamin D appears to b

224 .6-fold higher in those with preadmission 25-hydroxyvitamin D values in the insufficient and deficien

225 line, median (interquartile range) plasma 25-hydroxyvitamin D was 17 ng/mL (13-22 ng/mL) and peaked b

226 Mean serum 25-hydroxyvitamin D was 26.3 +/- 11.2 ng/ml and mean parath

227 wo cohorts, we observed that higher serum 25-hydroxyvitamin D was associated with a higher perceived

228 : Preadmission 25-hydroxyvitamin D was categorized as deficiency in 25-hyd

229 tography-tandem mass spectrometry method, 25-hydroxyvitamin D was measured in stored baseline serum s

230 patients, 18 years old or older, in whom 25-hydroxyvitamin D was measured prior to hospitalization b

231 dicted the three clinical outcomes; total 25-hydroxyvitamin D was not inferior to the other measures.

232 ect of weight loss on the change in serum 25-hydroxyvitamin D was shown overall.

233 olecalciferol-treated patients, change in 25-hydroxyvitamin D was strongly correlated with change in

234 Serum concentrations of vitamin A and 25-hydroxyvitamin D were significantly reduced after duoden

235 e resulted in a greater increase in serum 25-hydroxyvitamin D with a mean difference of 3.11 nmol/L (

236 tes, demonstrated an association of total 25-hydroxyvitamin D with hospital length of stay (incident

237 udy and found that the association of low 25-hydroxyvitamin D with increased secondary CVD event risk

238 emained significant associations of total 25-hydroxyvitamin D with readmission (odds ratio per 1 ng/m

239 he link between season of birth, neonatal 25-hydroxyvitamin D(3) [25(OH)D(3)] status, and adult cardi

240 N-terminal pro-brain natriuretic peptide, 25-hydroxyvitamin D) and 2 nonhormones (prostate-specific a

241 and high circulating levels of calcidiol (25-hydroxyvitamin D) each increased serum FGF23 levels in w

242 arkers (parathyroid hormone, calcium, and 25-hydroxyvitamin D), and annualized BMD reduction over a 8

243 , respectively, were as follows: 1) total 25-hydroxyvitamin D, 3% (-3% to 8%), 49% (30-82%), and 69%

244 9% (55-106%) (p < 0.001); 2) bioavailable 25-hydroxyvitamin D, 4% (-8% to 7%), 45% (40-70%), and 96%

245 en parathyroid hormone (PTH), circulating 25-hydroxyvitamin D, and markers of mineral metabolism and

246 and on days 3, 5, and 7, to assess total 25-hydroxyvitamin D, as well as vitamin D-binding protein a

247 per week, exercise per week, and current 25-hydroxyvitamin D, higher neonatal 25(OH)D(3) (per 50 nmo

248 he addition of serum calcium, phosphorus, 25-hydroxyvitamin D, intact parathyroid hormone, and 24,25-

249 ect of high circulating concentrations of 25-hydroxyvitamin D, local osteoblastic conversion of 25-hy

250 iomarkers on the metabolic pathway (e.g., 25-hydroxyvitamin D, parathyroid hormone, phosphorus) had l

251 ls of vitamin D-binding protein and total 25-hydroxyvitamin D, respectively.

252 birth, breastfeeding) and in adult life (25-hydroxyvitamin D, sun exposure, vitamin D intake from da

253 idney stones was not modified by baseline 25-hydroxyvitamin D, vitamin D dose and duration, or calciu

254 ifiable biological factor downstream from 25-hydroxyvitamin D, was responsible for the majority of th

255 nt mast cell activation through mast cell-25-hydroxyvitamin D-1alpha-hydroxylase (CYP27B1) and mast c

256 maintenance leads to an increase in serum 25-hydroxyvitamin D.

257 ein and albumin to calculate bioavailable 25-hydroxyvitamin D.

258 re or any interaction between retinol and 25-hydroxyvitamin D.

259 e excretion and inhibits hydroxylation of 25-hydroxyvitamin D.

260 tion and regulates the bioavailability of 25-hydroxyvitamin D.

261 n D 1-alpha-hydroxylase, which produces 1,25-hydroxyvitamin D.

262 ivity, plasma C-peptide, adiponectin, and 25-hydroxyvitamin D.

263 ciated with lower concentrations of serum 25-hydroxyvitamin D; however, uncertainty exists as to the

264 /MS) method for measuring 25(OH)D (sum of 25-hydroxyvitamin D2 and 25-hydroxyvitamin D3), calibrated

265 t-soluble vitamins all-trans retinol (A), 25-hydroxyvitamin D2, 25-hydroxyvitamin D3, alpha-tocophero

266 (LOD) for the low-concentration analytes (25-hydroxyvitamin D2, 25-hydroxyvitamin D3, and phylloquino

267 eficiency was defined as a serum level of 25-hydroxyvitamin D3 < 20 ng/mL (equivalent to < 50 nM) bef

268 Intervention with a single dose of 25-hydroxyvitamin D3 (25(OH)D) is capable of suppressing ma

269 , we used a case-cohort design to compare 25-hydroxyvitamin D3 (25(OH)D3 ) levels among infants with

270 We assessed whether 25-hydroxyvitamin D3 (25(OH)D3) was associated with risk of

271 fferent races and the association between 25-hydroxyvitamin D3 (25[OH]D) levels in pregnancy and the

272 nvestigated the association between serum 25-hydroxyvitamin D3 (25[OH]D3) levels and food allergy at

273 Three hundred fifty-nine pretreatment 25-hydroxyvitamin D3 (25[OH]D3) serum levels from the RICOV

274 precursor metabolite in the circulation, 25-hydroxyvitamin D3 (25OHD3), can influence IgE-mediated m

275 synthesize calcitriol from its precursor 25-hydroxyvitamin D3 (inactive precursor) [25(OH)D] upon an

276 nscription of Cyp24a1 encoding the enzyme 25-hydroxyvitamin D3 24-hydroxylase involved in the catabol

277 Klotho is a potent regulator of 1,25-hydroxyvitamin D3 [1,25(OH)2D3] formation and calcium-ph

278 n skin cells that produce the noncalcemic 20-hydroxyvitamin D3 [20(OH)D3] and 20,23-dihydroxyvitamin

279 tion during childhood.We examined whether 25-hydroxyvitamin D3 [25(OH)D3] concentrations in stored ne

280 25-Hydroxyvitamin D3 [25(OH)D3] has recently been found to

281 tion of target genes.In placental tissue, 25-hydroxyvitamin D3 [25(OH)D3] was strongly correlated (r

282 We described the distribution of 25-hydroxyvitamin D3 [25(OH)D3], 3-epi-25(OH)D3, and 25(OH)

283 skin of female mice and normalized serum 25-hydroxyvitamin D3 and 1,25-dihydroxyvitamin D3 levels, a

284 rds having more access to sunlight, while 25-hydroxyvitamin D3 concentration was higher (P<0.05) only

285 25-hydroxyvitamin D3 concentrations were significantly lowe

286 in D3 metabolism at all stages and plasma 25-hydroxyvitamin D3 depletion in the acute and latent phas

287 1alpha-Hydroxyvitamin D3 did not increase OCR.

288 that only lifelong treatment raised serum 25-hydroxyvitamin D3 from 173 nmol/L in controls to 290 nmo

289 rence between retention of vitamin D3 and 25-hydroxyvitamin D3 in eggs was shown.

290 estigated the retention of vitamin D3 and 25-hydroxyvitamin D3 in eggs, vitamin D3 in margarine, and

291 Levels of 25-hydroxyvitamin D3 increased with vitamin D3 plus calcium

292 had significantly lower concentrations of 25-hydroxyvitamin D3 than patients with either mild sepsis

293 Concentration of 25-hydroxyvitamin D3 was higher (P<0.05) in July and Septem

294 25(OH)D (sum of 25-hydroxyvitamin D2 and 25-hydroxyvitamin D3), calibrated to standard reference mat

295 -trans retinol (A), 25-hydroxyvitamin D2, 25-hydroxyvitamin D3, alpha-tocopherol (E), gamma-tocophero

296 king a 1alpha-hydroxyl group (vitamin D3, 25-hydroxyvitamin D3, and 24R,25-dihydroxyvitamin D3) decre

297 entration analytes (25-hydroxyvitamin D2, 25-hydroxyvitamin D3, and phylloquinone) were 25, 17, and 0

298 ), is synthesized by the essential enzyme 25-hydroxyvitamin D3-1alpha-hydroxylase (CYP27B1), which ca

299 ions in the vitamin D catabolizing enzyme 25-hydroxyvitamin D3-24-hydroxylase (CYP24A1) were describe

300 te on the concentration of vitamin D3 and 25-hydroxyvitamin D3.